抗抑郁药物与眼部因素和新生血管性年龄相关性黄斑变性抗VEGF再治疗需求的关系
本研究分析两项相同的前瞻性2年可变剂量方案(ranibizumab或aflibercept)数据,纳入206例患者(227眼),其中19例使用抗抑郁药物。多因素分析显示抗VEGF再治疗需求与抗抑郁药物使用(p=0.027)、第3个月较厚中央视网膜厚度(p<0.0001)及第3个月PED高度(p=0.001)显著相关。
要点
- 使用抗抑郁药物的nAMD眼更常出现色素上皮脱离(PED,p=0.04)。
- 抗VEGF再治疗需求与抗抑郁药物使用显著相关(p=0.027)。
- 第3个月中央视网膜厚度较厚(p<0.0001)和PED高度较高(p=0.001)与再治疗需求显著相关。
核心结论
- 抗抑郁药物治疗可能增加nAMD患者抗VEGF再治疗需求,可能通过抗抑郁药物、抑郁状态与VEGF水平的相互作用实现。
研究设计与样本
- 分析两项相同的前瞻性2年治疗协议数据,使用ranibizumab或aflibercept可变剂量方案(「Observe-and-Plan」),纳入206例患者(227眼),其中19例使用抗抑郁药物。
主要发现
- 使用抗抑郁药物的nAMD眼更常出现PED(p=0.04)。
- 多因素分析显示抗VEGF再治疗需求与抗抑郁药物使用显著相关(p=0.027)。
- 多因素分析显示抗VEGF再治疗需求与第3个月中央视网膜厚度较厚显著相关(p<0.0001)。
- 多因素分析显示抗VEGF再治疗需求与第3个月PED高度较高显著相关(p=0.001)。
关键数值与推荐
- 抗抑郁药物使用与再治疗需求的关联p=0.027。
- 第3个月中央视网膜厚度与再治疗需求的关联p<0.0001。
- 第3个月PED高度与再治疗需求的关联p=0.001。
- 使用抗抑郁药物者PED发生率p=0.04。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF retreatment in patients with nAMD and antidepressant medication, and the potential impact of ocular structural factors. METHODS: Data from two identical prospective 2-year treatment protocols using ranibizumab or aflibercept in a variable-dosing regimen ('Observe-and-Plan') were analysed. Retreatment requirement was compared with antidepressant medication intake (primary outcome) and a variety of ocular factors from baseline and from month 3 response (secondary outcomes), using univariate and multivariate analyses. RESULTS: Of the 206 included patients (227 eyes), 19 were on antidepressant medication. Their nAMD eyes significantly more often had pigment epithelium detachment (PED, p=0.04). Multivariate analysis revealed a significant association between anti-VEGF retreatment requirement and antidepressant medication use (p=0.027), as well as thicker central retinal thickness at month 3 (p<0.0001) and month 3 PED height (p=0.001). CONCLUSION: This study provides evidence that treatment with antidepressant medication increases the anti-VEGF retreatment requirement in patients with nAMD, possibly through the interplay of antidepressant medication, depression status and VEGF levels.
引用
- Mantel I, Zola M, Mir O, et al. Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration. Br J Ophthalmol. 2018. PMID: 30030393. doi:10.1136/bjophthalmol-2018-312318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。